After Claude 3.7 Sonnet launch, Anthropic secures €3.3B funding, valuation soars to €58.3B

Anthropic, an AI safety and research company, announced that it has raised $3.5B (approximately €3.3B) in a Series E round at a $61.5B (approximately €58.3B) post-money valuation.

The round was led by Lightspeed Venture Partners, with participation from Bessemer Venture Partners, Cisco Investments, D1 Capital Partners, Fidelity Management & Research Company, General Catalyst, Jane Street, Menlo Ventures and Salesforce Ventures, among other new and existing investors.

The company will use this investment to improve its next-generation AI systems, increase its computing capacity, enhance research on interpretability and alignment, and accelerate its global expansion.

The announcement comes as the company’s business is witnessing a significant growth. Anthropic’s annual revenue run rate was reportedly around $1B last year and the number has increased by 30 per cent so far in 2025 as the company rakes in cash from the API that serves its models and sells more subscriptions to its AI chatbot, Claude, reports TechCrunch.

The company told investors that it expects to burn $3B this year, according to The Information.

Anthropic’s Claude 3.7 Sonnet and Code

Last week after the launch of Claude 3.7 Sonnet and Claude Code. Claude 3.7 Sonnet has set a new high-water mark in coding abilities—an area where the company plans to make further progress in the coming months.

Claude Code is an active collaborator that can search and read code, edit files, write and run tests, commit and push code to GitHub, and use command line tools—keeping you in the loop at every step.

Building on this foundation, the company is focused on developing AI systems that can serve as true collaborators, working alongside teams to tackle complex projects, synthesise information across fields, and help organisations achieve outsized impact.

Businesses across industries—from startups like Cursor and Codeium to global corporations like Zoom, Snowflake, and Pfizer—are turning to Claude to transform their operations.